Trial Profile

A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and a PD-1 Inhibitor in Chronic Hepatitis B Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JNJ 73763989 (Primary) ; Entecavir; Nivolumab; Tenofovir alafenamide; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Therapeutic Use
Acronyms OCTOPUS-1
Sponsors Janssen Research & Development; Janssen-Cilag

18 Jul 2024 Status changed from active, no longer recruiting to completed.
08 Jun 2024 According to Interim results presented at the European Association for the Study of the Liver Congress 2024, treatment was generally safe and well tolerated but administration of low-dose nivolumab in the study was terminated due to observed TSH suppression.
26 Mar 2024 Planned End Date changed from 29 May 2024 to 30 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com